AxoGen, Inc. (NASDAQ:AXGN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

AxoGen, Inc. (NASDAQ:AXGN) has been given an average rating of “Moderate Buy” by the eleven analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $46.50.

AXGN has been the topic of several research reports. Citizens Jmp increased their target price on AxoGen from $42.00 to $50.00 and gave the stock a “market outperform” rating in a research report on Wednesday, April 29th. Lake Street Capital increased their target price on AxoGen from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Canaccord Genuity Group increased their target price on AxoGen from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Raymond James Financial reaffirmed an “outperform” rating and issued a $48.00 target price on shares of AxoGen in a research report on Wednesday, April 29th. Finally, Wall Street Zen lowered AxoGen from a “buy” rating to a “hold” rating in a research report on Saturday.

Insider Transactions at AxoGen

In related news, Director John Johnson sold 11,050 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $43.26, for a total value of $478,023.00. Following the transaction, the director directly owned 11,050 shares of the company’s stock, valued at approximately $478,023. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Amy Mcbride Wendell sold 1,647 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $42.60, for a total value of $70,162.20. Following the completion of the transaction, the director directly owned 93,826 shares in the company, valued at $3,996,987.60. This trade represents a 1.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 34,262 shares of company stock valued at $1,440,250. Corporate insiders own 2.44% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. MCF Advisors LLC purchased a new position in AxoGen in the fourth quarter valued at about $30,000. Aquatic Capital Management LLC raised its position in AxoGen by 287.8% in the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares during the period. Arax Advisory Partners raised its position in AxoGen by 362.4% in the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 819 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in AxoGen in the fourth quarter valued at about $36,000. Finally, Kestra Advisory Services LLC purchased a new position in AxoGen in the fourth quarter valued at about $39,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Trading Up 3.4%

Shares of AxoGen stock opened at $42.87 on Wednesday. AxoGen has a fifty-two week low of $9.22 and a fifty-two week high of $45.83. The firm has a market cap of $2.28 billion, a PE ratio of -66.98 and a beta of 1.12. The business’s fifty day moving average is $38.76 and its two-hundred day moving average is $34.28. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%.The business had revenue of $61.46 million for the quarter, compared to analysts’ expectations of $57.85 million. Analysts anticipate that AxoGen will post -0.37 earnings per share for the current year.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.